

Cruz I, et al. *Epicardial adipose tissue volume is not an independent predictor of atrial fibrillation recurrence after catheter ablation. Rev Esp Cardiol. 2022*

SUPPLEMENTARY DATA

METHODS

Cardiac adipose tissue measurements

As part of the preprocedural cardiac CT evaluation, 1 noncontrast acquisition was performed, with the following scan parameters: collimation, 24 × 1.2 mm; gantry rotation time, 330 ms; pitch, 0.2; tube voltage, 120 kV; and tube current, 190 mAs. Image reconstruction was performed using an effective slice thickness of 3 mm.

Table 1 of the supplementary data. Definitions of variables

Characteristic	Definition
Paroxysmal AF	AF episodes terminated (spontaneously or medically) within 7 d of onset
Persistent AF	AF episodes sustained beyond 7 d, including terminated by cardioversion after 7 d
Obesity	BMI \geq 30 kg/m ²
Coronary artery disease	Stenosis greater than 50% or previous revascularization procedure
Pulmonary disease	Chronic obstructive pulmonary disease or asthma
Dilated LA	LA volume greater than 34 mL/m ² , or diameter greater than 40 mm for men and 38 mm for women when the first value was missing

AF, atrial fibrillation; BMI, body mass index; LA, left atrium.

Cruz I, et al. Epicardial adipose tissue volume is not an independent predictor of atrial fibrillation recurrence after catheter ablation. *Rev Esp Cardiol.* 2022

Table 2 of the supplementary data. Uni- and multivariable Cox regression of adipose tissue measurements as a dichotomous variable and as a continuous value indexed to BSA for total atrial fibrillation recurrence

AT measurement	No. of events/no. at risk	Univariable model		No. of events/no. at risk	Multivariable model*	
		HR (95%CI)	P		HR (95%CI)	P
EATV ≥ 80 mL	123/350	1.59 (1.12-2.27)	.010	110/317	1.17 (0.79-1.73)	.4
EATVI	95/280	1.02 (1.01-1.03)	<.001	91/267	1.01 (1.00-1.02)	.10
PATV ≥ 150 mL	123/350	1.51 (1.06-2.15)	.023	110/317	1.03 (0.68-1.55)	.9
PATVI	95/280	1.01 (1.00-1.02)	<.001	91/267	1.01 (1.00-1.01)	.14
Attenuation EAT posterior to LA < -75 HU	120/338	1.04 (0.72-1.50)	.8			

95%CI, 95% confidence interval; AT, adipose tissue; EATV, epicardial adipose tissue volume; EATVI, epicardial adipose tissue volume indexed to total body surface area (BSA); HR, hazard ratio; LA, left atrium; PATV, pericardial adipose tissue volume; PATVI, pericardial adipose tissue volume indexed to BSA.

*Adjusted for age, sex, hypertension, diabetes, obesity, atrial fibrillation subtype, and dilated LA.

Table 3 of the supplementary data. Multivariable Cox regression parameters of the covariables used for adjustment in the multivariable model for AF recurrence

Covariables	AT as dichotomous variable		AT as continuous variable, indexed to BSA	
	EATV ≥ 80 mL HR (95%CI), P	PATV ≥ 150 mL HR (95%CI), P	EATVI HR (95%CI), P	PATVI HR (95%CI), P
Age	1.02 (1.00-1.04), .089	1.02 (1.00-1.04), .069	1.02 (0.99-1.04), .2	1.02 (0.99-1.04), .2
Sex, female	1.43 (0.93-2.21), .1	1.43 (0.92-2.22), .1	1.32 (0.81-2.13), .3	1.52 (0.83-2.21), .2
Hypertension	0.87 (0.57-1.33), .5	0.85 (0.56-1.30), .5	0.85 (0.54-1.33), .5	0.84 (0.53-1.33), .5
DM	1.10 (0.63-1.92), .7	1.10 (0.63-1.92), .7	1.09 (0.61-1.96), .8	1.10 (0.61-1.97), .7
Obesity	1.29 (0.82-2.05), .3	1.32 (0.82-2.12), .3	1.56 (0.93-2.61), .089	1.57 (0.92-2.68), .1
AF subtype (persistent)	2.12 (1.38-3.26), .001	2.13 (1.38-3.29), <.001	1.90 (1.17-3.08), .009	1.89 (1.16-3.10), .011
Dilated LA	1.32 (0.82-2.13), .2	1.32 (0.82-2.12), .3	1.30 (0.76-2.23), .3	1.30 (0.76-2.23), .3

95%CI, 95% confidence interval; AT, adipose tissue; DM, diabetes mellitus; EATV, epicardial adipose tissue volume; EATVI, epicardial adipose tissue volume indexed to BSA; HR, hazard ratio; PATV, pericardial adipose tissue volume; PATVI, pericardial adipose tissue volume indexed to BSA.


Table 4 of the supplementary data. Uni- and multivariable Cox regression of adipose tissue measurements for atrial fibrillation recurrence according to atrial fibrillation subtype

AT Measurement	No. of Events/No. at risk	Univariable model		No. of Events/No. at risk	Multivariable model*	
		HR (95%CI)	P		HR (95%CI)	P
<i>Paroxysmal atrial fibrillation</i>						
EATV ≥ 80 mL	75/275	2.01 (1.28-3.17)	.002	68/ 250	1.31 (0.79-2.16)	.3
EATVI	62/222	1.02 (1.01-1.03)	<.001	59/212	1.01 (0.99-1.02)	.2
PATV ≥ 150 mL	75/275	1.95 (1.24-3.07)	.004	68/250	1.25 (0.73-2.13)	.4
PATVI	62/222	1.01 (1.00-1.02)	.004	59/212	1.00 (0.99-1.01)	.4
<i>Persistent AF</i>						
EATV ≥ 80 mL	38/74	0.92 (0.48-1.75)	.8	34/67	0.62 (0.27-1.42)	.3
EATVI	28/58	1.00 (0.98-1.02)	.9	27/55	0.99 (0.97-1.01)	.5
PATV ≥ 150 mL	38/74	0.76 (0.4-1.44)	.4	34/67	0.44 (0.18-1.05)	.064
PATVI	28/58	1.00 (0.99-1.01)	.9	27/55	1.00 (0.98-1.01)	.5

95%CI, 95% confidence interval; EATV, epicardial adipose tissue volume; HR, hazard ratio; PATV, pericardial adipose tissue volume; EATVI, epicardial adipose tissue volume indexed to body surface area (BSA); PATVI, pericardial adipose tissue volume indexed to BSA.

*Adjusted for age, sex, hypertension, diabetes, obesity, and dilated left atrium.

Figure 1 of the supplementary data. Partial effect curves obtained with the logistic regression model with a restricted cubic polynomial transformation of *a)* EAT volume, *b)* PAT volume, and *c)* attenuation EAT posterior to left atrium, and atrial fibrillation recurrence as the outcome.



EAT, epicardial adipose tissue; PAT, pericardial adipose tissue.